- Researchers at the John Wayne Cancer Institute are looking at usingPseudomonas exotoxin to treat brain tumors, and have received US Food and Drug Administration approval to commence Phase I/II trials with the poison and its delivery system. As cancer cells have functional receptors for interleukin-4, this is used as a targeting vector to deliver the exotoxin to the tumor. Preclinical models have demonstrated that, within a number of hours following administration, the toxin destroys the tumor cell's ability to produce protein. Thus within two to three weeks, most tumors will shrink, say the researchers.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze